Peps
What is Enfuvirtide?
Enfuvirtide is an HIV fusion inhibitor with historical combination-treatment evidence. MedlinePlus reports that the injection has been discontinued in the United States.
Biological role or research focus
Combination antiretroviral treatment.
The treatment was added to an optimized regimen, so its use is not equivalent to monotherapy. Short-term viral and cell-count outcomes are distinct from long-term clinical outcomes.
Role reference: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. · 2003 ↗
Names you may encounter
T-20
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- HIV fusion-inhibitor peptide
- Research focus
- Combination antiretroviral treatment
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Molecular structure
How Enfuvirtide works
It interferes with HIV fusion through the viral entry machinery. Antiviral activity against a specific virus is different from a nonspecific “immune boost.”
Medicine status & clinical context
MedlinePlus now states that enfuvirtide injection has been discontinued in the United States and that its monograph is no longer updated. Historical HIV trial results remain relevant to the evidence record, but should not be read as evidence of current U.S. availability. For other countries, consult current local product information.
The selected study evaluates combination HIV treatment in a treatment-experienced population. It does not establish standalone treatment, general infection prevention, or a consumer immune-support use.
Source: MedlinePlus · Enfuvirtide · U.S. discontinuation notice ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2003
TORO-1
Did adding enfuvirtide improve viral-load and CD4 outcomes?
- Population / model
- 501 people with HIV and substantial prior antiretroviral treatment or resistance.
- Study design
- Randomized open-label comparison of enfuvirtide plus optimized background therapy with optimized background therapy alone; 24-week analysis.
- Main finding
- Viral load fell by 1.696 versus 0.764 log10 copies per milliliter. CD4 counts increased by 76 versus 32 cells per cubic millimeter.
- Limits & context
- The treatment was added to an optimized regimen, so its use is not equivalent to monotherapy. Short-term viral and cell-count outcomes are distinct from long-term clinical outcomes.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Enfuvirtide. ↗
Drugs · 2003 · Journal Article, Review
Enfuvirtide. ↗
· 2012 · Review
Enfuvirtide. ↗
Expert opinion on investigational drugs · 2002 Dec · Journal Article, Review
Enfuvirtide. ↗
Nature reviews. Drug discovery · 2003 May · Journal Article
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Injection-site reactions occurred in 98% of enfuvirtide recipients. Pneumonia was reported more frequently in the enfuvirtide group. Specialist combination-treatment decisions require complete medicine information.
Identity, route, and evidence limits
The treatment was added to an optimized regimen, so its use is not equivalent to monotherapy. Short-term viral and cell-count outcomes are distinct from long-term clinical outcomes.
Official product context · checked October 4, 2026
The linked medication monograph is archived in the sense that it is no longer being updated following U.S. discontinuation. Historical safety information and trial preparations are not substitutes for current local product labeling.
Source: MedlinePlus · Enfuvirtide · U.S. discontinuation notice ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Is enfuvirtide a general immune-enhancement peptide?
- What population, comparator, and route were actually studied?
- The treatment was added to an optimized regimen, so its use is not equivalent to monotherapy. Short-term viral and cell-count outcomes are distinct from long-term clinical outcomes.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is enfuvirtide a general immune-enhancement peptide?
No. Its mechanism and trial concern HIV entry inhibition within a specialist antiretroviral regimen.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Is enfuvirtide currently available in the United States?
No. MedlinePlus reports U.S. discontinuation; availability elsewhere requires current local product information.
Source: MedlinePlus · Enfuvirtide · U.S. discontinuation notice ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.